Veeva Systems (NYSE:VEEV – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.
Profitability
This table compares Veeva Systems and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veeva Systems | 29.34% | 14.25% | 11.71% |
| Aclarion | -10,948.81% | -59.34% | -56.12% |
Analyst Recommendations
This is a summary of current ratings and target prices for Veeva Systems and Aclarion, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veeva Systems | 1 | 8 | 19 | 0 | 2.64 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
Veeva Systems currently has a consensus target price of $309.08, suggesting a potential upside of 1.60%. Aclarion has a consensus target price of $7.50, suggesting a potential upside of 351.81%. Given Aclarion’s higher possible upside, analysts plainly believe Aclarion is more favorable than Veeva Systems.
Risk and Volatility
Veeva Systems has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.
Insider & Institutional Ownership
88.2% of Veeva Systems shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 10.6% of Veeva Systems shares are held by insiders. Comparatively, 0.0% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Veeva Systems and Aclarion”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veeva Systems | $3.20 billion | 15.42 | $908.91 million | $6.08 | 50.04 |
| Aclarion | $80,000.00 | 59.76 | -$7.23 million | ($7.40) | -0.22 |
Veeva Systems has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks.
Summary
Veeva Systems beats Aclarion on 11 of the 14 factors compared between the two stocks.
About Veeva Systems
Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.
